Dr Lal Pathlabs Ltd (LALPATHLAB)
₹1,915.30
Mkt cap
₹32,088 Cr
P/E ratio
57.10
P/B
12.77
Div yield
0.73%
ROE
22.30%
ROCE
28.00%
EPS (TTM)
₹33.54
Book value
₹150
52W range
1,273–2,039
Sector
Healthcare
Price history
Previous close
Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates. [1]
NSE LALPATHLABBSE 539524
Health check
Constructive
ValuationExpensive
ProfitabilityStrong
GrowthModerate
TechnicalsBullish
52-week range
−6.05% from high₹1,915
₹1,273+50.50% from low₹2,039
Current
₹1,915.30
Prev close
₹1,915.00
Day
+0.02%
Price performance
1D
+0.02%
1W
+4.19%
1M
−1.80%
3M
+1.94%
6M
+37.02%
1Y
+24.71%
YTD
+29.92%
Financials
Revenue, profit & margin
P/E ratio
57.1×
LALPATHLAB is 40% above the sector median of 40.7×
LALPATHLAB57.1×
Sector median40.7×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 541 | 601 | 539 | 545 | 602 | 660 | 597 | 603 | 670 | 731 | 660 | 703 | 798 | |
| Expenses | 395 | 424 | 398 | 401 | 432 | 458 | 443 | 434 | 478 | 506 | 480 | 516 | 550 | |
| Operating Profit | 146 | 178 | 141 | 145 | 170 | 202 | 154 | 169 | 192 | 224 | 179 | 187 | 248 | |
| OPM % | 27% | 30% | 26% | 27% | 28% | 31% | 26% | 28% | 29% | 31% | 27% | 27% | 31% | |
| Other Income | 14 | 18 | 18 | 18 | 21 | 22 | 25 | 26 | 28 | 25 | -6 | 24 | 32 | |
| Interest | 8 | 8 | 7 | 7 | 6 | 6 | 5 | 5 | 5 | 5 | 7 | 6 | 6 | |
| Depreciation | 35 | 36 | 36 | 37 | 35 | 35 | 36 | 36 | 35 | 40 | 42 | 45 | 44 | |
| Profit before tax | 118 | 152 | 116 | 120 | 150 | 183 | 138 | 153 | 181 | 204 | 124 | 160 | 229 | |
| Tax % | 29% | 27% | 29% | 28% | 28% | 29% | 29% | -1% | 26% | 25% | 26% | 17% | 25% | |
| Net Profit | 84 | 111 | 82 | 86 | 108 | 131 | 98 | 156 | 134 | 152 | 91 | 132 | 170 | |
| EPS in Rs | 4.95 | 6.55 | 4.87 | 5.06 | 6.37 | 7.73 | 5.78 | 9.26 | 7.90 | 8.99 | 5.40 | 7.84 | 10.11 | |
| Raw PDF |
Earnings
Results dates & reactionsNext results
4 Nov '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +0.27% · closed higher next day 20 of last 39
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 2 Nov '23◦ | 1 Feb '24◦ | 10 May '24◦ | 7 Aug '24◦ | 23 Oct '24◦ | 30 Jan '25◦ | 25 Apr '25◦ | 31 Jul '25 | 31 Oct '25 | 30 Jan '26 | 30 Apr '26 | 24 Jul '26 |
| Earnings day | +5.34% | −1.85% | +6.24% | −2.69% | −6.35% | −0.86% | −3.42% | +1.67% | +1.49% | +1.02% | −2.19% | +4.27% |
| +1 day | +7.46% | −3.13% | +6.12% | −1.92% | −3.63% | −0.57% | −4.58% | +2.52% | +5.36% | +1.61% | +12.56% | +8.30% |
| +5 days | +8.68% | −1.91% | +8.00% | +0.80% | −4.38% | −2.51% | −3.55% | +3.68% | 0.00% | +3.45% | +18.03% | +12.93% |
| +15 days | +7.49% | −2.06% | +13.90% | +4.36% | −8.84% | −8.77% | −3.09% | +8.90% | +1.03% | +0.51% | +16.62% | +13.59% |
| +30 days | +2.84% | −19.53% | +15.80% | +0.53% | −2.75% | −11.63% | +1.68% | +6.42% | −7.45% | −3.88% | +15.61% | +11.29% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 4 Per Share | 4.00 | 25 Jun '26 | 26 Jun '26 |
Shareholding
as of Sep 202652.93%Promoter
Promoters52.93%0.26
FIIs18.73%1.38
DIIs21.57%0.02
Public6.35%1.13
Government0.00%0.01
Ownership trend
Peers
7 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Dr Lal Pathlabs | ₹1,911.70 | 57.07 | 32,088 | 0.73% | 171 | +28.02% | 798 | +19.10% | 28.00% |
| Vijaya Diagnost. | ₹1,464.20 | 80.44 | 15,081 | 0.14% | 53 | +37.60% | 231 | +22.83% | 20.53% |
| Metropolis Healt | ₹553.85 | 55.20 | 11,490 | 0.36% | 57 | +25.77% | 450 | +16.62% | 17.81% |
| Thyrocare Tech. | ₹515.50 | 46.83 | 8,205 | 1.81% | 15 | −11.56% | 271 | +25.07% | 35.38% |
| Nephrocare Health Services | ₹628.55 | 74.26 | 6,321 | 0.00% | 32 | +34.89% | 282 | +23.69% | 15.34% |
| Suraksha Diagno. | ₹319.55 | 46.49 | 1,664 | 0.16% | 13 | +38.40% | 88 | +20.75% | 17.29% |
| Krsnaa Diagnost. | ₹497.95 | 16.33 | 1,615 | 0.40% | 16 | −19.12% | 211 | +19.95% | 12.71% |
| Median: 16 Co. | ₹377.02 | 40.70 | 1,027 | 0.07% | 13 | +25.77% | 103 | +19.10% | 21.90% |
Filings
Annual reports11
Concall transcripts124
TranscriptJul 2026PPTJul 2026RECJul 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025TranscriptMay 2025PPTMay 2025RECMay 2025TranscriptFeb 2025PPTFeb 2025TranscriptOct 2024PPTOct 2024TranscriptAug 2024PPTAug 2024TranscriptMay 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 27 Oct - Q2 and H1 FY27 earnings conference call on November 4, 2026 at 6:00 PM IST.Corporate Action-Board to consider Dividend 27 OctUpdate on board meeting 27 Oct - Board meeting on November 4, 2026 to approve Q2 results and consider second interim dividend.Announcement under Regulation 30 (LODR)-Acquisition 13 Oct - PUPL acquired remaining 30% stake in Centrapath Labs on October 13, 2026, making CPL wholly owned.Announcement under Regulation 30 (LODR)-Acquisition 12 Oct - Dr Lal PathLabs invests up to Rs 30.3 crore in PUPL to acquire remaining 30% in CPL.